Clinical Trial

Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome

Name: Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome — clinical trial record (NCT07654114)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FXS-CTH120-01

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this Phase IIa study is to evaluate the safety, tolerability, and effectiveness of CTH120 in adult males with Fragile X syndrome.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-06-12.

Trial Details

NCT Number	NCT07654114
Lead Sponsor	Connecta Therapeutics, S.L. Collaborators: Hospital del Mar Research Institute (IMIM), Corporacion Parc Tauli, Ministry of Science and Innovation, Spain, Astrum CRO, S.L.
Conditions	Fragile X Syndrome (FXS), Fragile X Syndrome
Enrollment	30 participants
Start Date	2026-05-21
Primary Completion	2027-05 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2026-07-17